Celerion has formed an alliance with non-profit healthcare organisation BryanLGH Health System to make a dedicated wing of BryanLGH Medical Center West in Lincoln, Nebraska available for early-stage clinical studies.
Lincoln is the home base of Celerion, the privately owned contract research organisation (CRO) formed in the US from the Early Stage Development operations and the Development and Regulatory Services consultancy of MDS Pharma Services, while BryanLGH Health System is locally owned.
The CRO will have access to 24 in-patient beds for early-stage trials, including Phase I and First-In-Human studies, in the newly launched Celerion-BryanLGH Clinical Research Unit.
The alliance gives pharmaceutical and biotechnology companies the opportunity to place clinical studies in a hospital environment, “thus increasing safety for study volunteers and improving access to hospital procedures and techniques”, Celerion said.
That includes round-the-clock emergency care and state-of-the-art hospital equipment such as chest X-rays, PET (positron emission tomography) scans and magnetic resonance imaging.
“This alliance affirms a major commitment by BryanLGH Health System to clinical research and is a natural extension of our medical expertise,” commented Kimberly Russel, president and chief executive officer of BryanLGH.
BryanLGH Medical Center is a 664-bed, not-for-profit healthcare organisation serving patients throughout Nebraska, as well as in parts of Kansas, Iowa, South Dakota and other states in the region.